OSF Healthcare Ventures contributed to a $102m series D round for Inflammatix, a developer of diagnostics systems for detecting infections.

Novo co-led an $81.5m round for the gene therapy developer that included Sarepta Therapeutics, UCB Ventures, Takeda Ventures and Alexandria Venture Investments.

Novo Nordisk, Insulet and Mayo Clinic helped the diabetes monitoring technology provider push its overall funding past $100m.

This is the first in a series of quarterly publications for the Global Health Council looking at drug development, healthcare providers such as hospitals and digital health, payments and patient wellness. This first article looks at the implications of the disease treatments coming out of advanced research and artificial intelligence and the broader shift to digitalisation in healthcare. The next issue will focus on the providers of healthcare.

Binoy Bhansali was previously at Sandbox Industries, which manages $1.2bn across four funds for health insurer Blue Cross Blue Shield.

Q&A with Kurt Sheline, principal, Echo Health Ventures

Konishiyasu and Sojitz contributed to a series A round for the cancer vaccine developer, which expanded to their home of Japan last year.

SoftBank Vision Fund 2, Itochu and an unnamed insurer took part in a series C round that hiked the gene and cell therapy developer's total funding to $845m.

IBM Ventures participated in a $20m round for the neurological disease diagnostics technology developer, a spinout from Tel Aviv University.

The ophthalmic treatment developer has now raised almost $36m in total, with CR-CP Life Science Fund having led a $25m round.